The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XIX.ck

Path: Lymphoproliferative disease, endothoracic

Publications

Tsuchiya K, Suzuki Y, Yasui H, Hozumi H, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Baba S, Suda T

Methotrexate-associated Lymphoproliferative Disorder with Diffuse Ground-Glass Opacities.

American journal of respiratory and critical care medicine 2019 Apr 15;199;1031-1033 — 2019 Apr 15 — 1031-1033

Watanabe H, Masuda R, Matsuzaki T, Hamanaka R, Ikoma Y, Nakano T, Oiwa K, Kohno M, Iwazaki M

A surgical case of methotrexate-associated lymphomatoid granuloma.

General thoracic and cardiovascular surgery 2018 Jul;66;435-438 — 2018 Jul — 435-438

Kamiya Y, Toyoshima M, Suda T

Endobronchial Involvement in Methotrexate-associated Lymphoproliferative Disease.

American journal of respiratory and critical care medicine 2016 06 01;193;1304-6 — 2016 06 01 — 1304-6